Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Harvard Bioscience ( (HBIO) ) has issued an announcement.
Harvard Bioscience is engaged in ongoing discussions to address its credit agreement with Citizens Bank, Wells Fargo Bank, and First-Citizens Bank & Trust Company. The company aims to complete the refinancing or repayment of this agreement by the fourth quarter of 2025, which could impact its financial operations and stakeholder interests.
The most recent analyst rating on (HBIO) stock is a Hold with a $0.76 price target. To see the full list of analyst forecasts on Harvard Bioscience stock, see the HBIO Stock Forecast page.
Spark’s Take on HBIO Stock
According to Spark, TipRanks’ AI Analyst, HBIO is a Neutral.
Harvard Bioscience’s stock score is primarily influenced by its weak financial performance and challenging valuation. Positive technical indicators and operational improvements noted in the earnings call provide some support, but are overshadowed by ongoing financial and market challenges.
To see Spark’s full report on HBIO stock, click here.
More about Harvard Bioscience
Average Trading Volume: 6,446,643
Technical Sentiment Signal: Sell
Current Market Cap: $32.23M
For an in-depth examination of HBIO stock, go to TipRanks’ Overview page.